The press release reflects in a succinct and understandable way the article published in Science by Dr. Drucker. The review is based on well-researched articles and clinical trials, either completed or in progress. It is a good study that addresses aspects that are currently being investigated on other possible actions of GLP1 and GIP analogues. Obviously, it is a limited publication type in its text, where more detailed information is not possible, but it expresses the most relevant data from current research both in preclinical trials and with well-referenced clinical trials.

This review takes as a reference clinical trials such as EVOKE, which has not yet published its definitive results, or others such as SELECT, which have already been completed. It also includes the conclusions of studies carried out on experimental animals, explaining adequately that they cannot be extrapolated to humans until they are tested. It simply presents evidence that opens up new fields of research in other pathologies that, as they rightly say, go beyond diabetes and obesity.

The article is based on the results of animal experiments; their results are always basic for further clinical research. Obviously, they cannot cover multiple fields, but they are the results of a well thought-out design. As for the data it provides from clinical trials, these have been approved by regulatory agencies such as the all-powerful FDA, which is a sign of assurance in terms of their design.

I believe that the contributions that these new findings can make, in some cases, to the comorbidities associated with diabetes and obesity and, in others, as neuroprotectors against neurological diseases or psychiatric disorders, are really important. The role of inflammation in all of them is the common thread and, although it is always advisable to be cautious and not to raise false expectations, science must continue to advance and this is an important step in this direction.